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T
he management of patients with ST segment elevation acute myocardial infarction has
evolved considerably during the last decades. Restoration of coronary flow can be achieved
pharmacologically by the administration of thrombolytic or fibrinolytic drugs, which are
widely available and easy to administer, or mechanically by means of percutaneous transluminal
coronary angioplasty (PTCA) with or without antecedent drug treatment, which is less available
and more complex to implement and carry out. The two strategies are currently subject of a vivid
debate by protagonists and antagonists of the two approaches. This paper summarises the
available evidence with emphasis on the randomised comparisons of direct PTCA with
thrombolysis. These studies and findings are open for interpretation. They are reviewed and
discussed, and a rational and pragmatic approach is proposed.
SCOPE OF THE PROBLEMc
Acute myocardial infarction (AMI) is a frequent clinical condition associated with a high
immediate and short term mortality and long term morbidity. The pre-hospital case fatality rate is
approximately 32%, and is most often caused by malignant arrhythmias.1 In-hospital mortality of
those patients who reach the hospital alive is 8–15%.1 w1 In case of survival, the patient may
become severely incapacitated because of heart failure as a result of the loss of normal
functioning myocardium and ventricular remodelling.w2
In almost all patients, AMI is caused by an acute thrombotic coronary occlusion following the
rupture of the cap of an atherosclerotic plaque.w3 The associated ischaemic injury and subsequent
myocardial necrosis spreads from the subendocardial to the subepicardial myocardium in a time
span of several hours.w4 Irreversible loss of subendocardial cardiomyocytes occurs after 30
minutes while subepicardial cardiomyocytes may survive for up to six hours. Therefore, to save
the patient from sudden death and to save the ventricle, thus preventing heart failure, early
diagnosis and treatment are imperative.
Myocardial salvage depends on the prompt, complete, and sustained restoration of myocardial
perfusion. At present, this can only be obtained by re-establishing coronary flow, although
coronary reperfusion does not necessarily imply myocardial perfusion.w5 In practice, the choice
between thrombolysis and PTCA depends on, among others, physician preferences, availability of
infrastructure, economic factors, and time of admission, rather than clinical evidence.2 w1 w6
THE CASE FOR THROMBOLYTIC TREATMENT
A vast number of trials have consistently and unequivocally proven that thrombolysis reduces
infarct size and mortality and improves long term outcome.3 The benefit of treatment is observed
in patients with different levels of risk. Patients who present early and who receive treatment
within two hours after onset of symptoms benefit the most (fig 1).3 4 Thrombolytic drugs can now
be administrated by a single bolus; thus, this approach is applicable in almost all circumstances
and can be started in the very early phase of AMI, even before hospital admission. Pre-hospital
initiation of treatment may save one hour in comparison to the in-hospital administration and is
associated with a fourfold higher incidence of aborted infarction (17.1% v 4.5%) and an absolute
reduction of 2.0% (relative 17%) in hospital mortality.5 w7 On-site initiation of treatment is the
unsurpassed opportunity of early management since public education has failed to make patients
seek help earlier.w8
Thrombolysis, nonetheless, has a number of limitations that affects its application and efficacy.
It fails to induce complete restoration of coronary flow (TIMI (thrombolyis in myocardial
infarction) grade 3) in 30–40% of the patients, and early reocclusion occurs in 5–6% of the
patients.w9 Because of the inherent risk of bleeding, thrombolysis cannot be used in patients with
bleeding disorders, those receiving anticoagulant drugs, or patients who have undergone recent
surgery or trauma. Intracranial haemorrhage is the most extreme complication. It occurs in
approximately 1% of patients but may exceed 2% depending on the number of risk factors
present.w10 Thrombolysis does not resolve the underlying plaque and stenosis. The residual
1352
www.heartjnl.com
 on 10 October 2006 heart.bmjjournals.comDownloaded from 
stenosis may cause ischaemia that may hamper ventricular
recovery. These limitations have stimulated the (re)appraisal
of mechanical reperfusion.
WHY DIRECT OR PRIMARY PTCA?
The first comparisons of PTCA without previous or con-
comitant thrombolytic treatment (direct or primary PTCA)
with in-hospital thrombolysis revealed that direct PTCA is
associated with a higher proportion of patients reaching TIMI
3 flow (90%), and a better left ventricular function, lower
incidence of mortality, reinfarction, stroke, recurrent ischae-
mia, and bleeding complications.6 7 Analysis of 23 rando-
mised studies confirmed the superiority of direct PTCA in the
reduction of death, reinfarction, and stroke at 30 days, even
when the patient is transferred from one hospital to the other
(table 1).8 As a result, direct PTCA became embraced as the
first choice treatment of AMI. It is in line with the proposal of
the National Heart Attack Alert Program to send patients
with an AMI to a PTCA centre, similar to trauma patients,
and not to the nearest hospital.w11 It dissents, however, with
the opinion of the NRMI investigators who found a similar
in-hospital and 90 day mortality rate in more than 305 000
patients, irrespective of the admission to a community or
tertiary referral center (table 2).2 They proposed to treat
patients with AMI at the closest medical facility, rather than
sending them to a regional centre with specialised facilities.
ARGUMENTS IN FAVOUR FOR REFERRING EVERY
PATIENT FOR DIRECT PTCA
The strongest argument for referring every patient for direct
PTCA is the better clinical outcome after direct PTCA
(table 1).8 An even better outcome after PTCA may have
occurred in these studies if state of the art PTCA techniques
had been used. Stents were used to a varying degree in only
50% of the studies and a glycoprotein IIb/IIIa receptor blocker
in only 25%, despite the superiority of stents over balloon
angioplasty to prevent restenosis, and the recognised value of
glycoprotein IIb/IIIa receptor blockers to prevent thrombotic
complications.w12 w13 This contrasts with the use of the most
powerful thrombolytic drug in patients assigned to thrombo-
lysis. Accelerated tissue plasminogen activator (acc t-PA),
which is associated with a higher TIMI 3 rate and survival
benefit than streptokinase, was used in most of the studies
and patients (69%).8 w14 Of note is the superiority of PTCA
when patients were transported from a community hospital
to a PTCA centre, despite a delay in the onset of treatment of
approximately 40 minutes (tables 3 and 4).8–10
Similarly, the outcome in the thrombolytic treated patients
may have been better with a more liberal use of rescue PTCA.
Rescue PTCA was applied in a minority of the patients, except
for those in the CAPTIM study (tables 3 and 4).9–11 The role of
systematic PTCA rather than rescue PTCA is unclear. The first
randomised studies failed to show an additional benefit of
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Figure 1 Left panel: Proportional 35 day mortality reduction is highest in patients treated within one hour (48%, 95% confidence interval (CI) 31% to
61%) and within two hours (44%, 95% CI 32% to 53%) versus those treated later (20%, 95% CI 15% to 25%). Right panel: Relation between absolute
benefit of thrombolytic treatment and treatment delay described by a linear and a non-linear function. There is a reduction in benefit of approximately
1.6 (0.5) lives per 1000 patients per hour treatment delay. Benefit of fibrinolytic treatment was (mean (SD)) 65 (14), 37 (9), 26 (6), and 29 (5) lives
saved per 1000 treated patients in the 0–1, 1–2, 2–3, and 3–6 hour intervals, respectively. Reproduced from Boersma et al,4 with permission.
Table 1 Short term clinical outcome after direct PTCA and thrombolytic treatment
PTCA Thrombolysis Odds ratio (95% CI)
Absolute risk
difference
Number to
treat
Patients (n) 3717 3720
Death 5.0 7.0 0.70 (0.6 to 0.9) 2.0 50
Non-fatal
reinfarction 3.0 7.0 0.35 (0.3 to 0.5) 4.0 25
Stroke 1.0 2.0 0.46 (0.3 to 0.7) 1.0 100
Intracranial
haemorrhage 0.05 1.0 0.05 (0.006 to 0.35) 0.95 105
Composite 8.0 14.0 0.5 (0.45 to 0.6) 6.0 16
Events are expressed in relative numbers (%).
Patients with AMI complicated by cardiogenic shock are not included in this analysis.w20
Modified from Keeley et al,8 with permission.
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systematic PTCA after thrombolysis, while a recent study
reported a better outcome when stent implantation was
performed within six hours after thrombolysis in comparison
to a delayed elective intervention at two weeks.12–15
COMMENTS AND UNRESOLVED ISSUES
The patients enrolled in the randomised studies may not be
representative of those seen in daily practice. In general, they
have a lower baseline risk because of the inclusion and
exclusion criteria (for example, eligibility for both thrombo-
lysis and PTCA) and selection bias. The open design,
physician preferences or prejudices, and logistical aspects
dictated by, for example, time of presentation may explain
the latter. In both the NRMI registry and the C-PORT study,
most patients underwent PTCA during the office hours.2 16
The initiation of treatment takes longer during out-of-office
hours, in particular for more complex treatments such as
PTCA. This may affect outcome since time to treatment is a
main determinant of outcome. This has been clearly
established for thrombolysis (fig 1) but is less apparent in
the case of PTCA.3 4 17 w15 w16 An increasing door-to-balloon
time was related to an increased mortality in one study, but
was not confirmed by two other analyses.17 w15 w16 Other data
suggest that direct PTCA is superior to thrombolysis provided
the added delay is less than 60–90 minutes.w17 Longer delays
are associated with increased mortality.w18 The established
relation between time and outcome in the thrombolytic
studies but discrepant findings in the PTCA studies may be
explained by the fact that few patients in the PTCA studies
were enrolled in the (very) early phase of AMI when most of
the salvage may be achieved.
Also, the results of the randomised studies may not be
repeated in less ideal settings. The NRMI investigators found
that the mortality at discharge was 3.4% after direct PTCA
compared with 5.4% after thrombolysis in high volume PTCA
centres (4.5% v 5.9% in intermediate volume centres, and
6.2% v 6.0% in low volume centres).18 With adequate
preparation and training, direct PTCA may be superior to
thrombolytic treatment in less experienced centres. The
C-PORT study compared direct PTCA with thrombolysis in
541 patients admitted to hospitals without on-site surgical
back up or a pre-existing PTCA programme.16 A significant
and sustained reduction in the incidence of the composite
adverse outcome of death (5.3% v 7.1%), recurrent infarction
(4.9% v 8.8%), and stroke (1.3% v 3.5%) was observed after
PTCA.
The incidence of mortality and reinfarction in the
randomised trials is lower than in population based surveys
and, despite a large relative reduction in events after direct
PTCA, the absolute difference in outcome between thrombo-
lysis and PTCA is much smaller (tables 1 and 2).1 2 w1 The
latter provides the estimate of the number of patients who
need to be treated to save one from a particular event and can
be used to evaluate treatment (table 1). Despite the small
absolute differences, the direction of benefit for all outcome
measures favours direct PTCA. This is especially true for
reinfarction, which is associated with a high mortality and
further deterioration of the ventricular function.
Costs and logistics need to considered as well. The costs of
direct PTCA increase considerably in hospitals without full
existing resources or with a low annual caseload.w19 In
addition, a lack of infrastructure may impede delivery of care.
Less than 10% and 25% of hospitals in Europe and the USA,
respectively, have PTCA facilities.w9 An acute PTCA pro-
gramme implies an availability of a dedicated medical and
paramedical team on a 24 hour/seven day a week basis.
Table 2 In-hospital events of patients with AMI admitted in different types of hospitals
Non-invasive
Cath capable
No PTCA PTCA capable PTCA and CABG capable
Patients (n) 57252 76956 24451 147153
Death 10.2 10.4 10.0 11.3
Reinfarction 2.4 2.4 2.6 2.7
Stroke 0.8 1.0 0.8 1.6
Major
bleeding
1.0 1.2 1.3 3.0
Events are expressed in relative numbers (%).
Modified from Rogers et al,2 with permission.
Table 3 Study design and use of reperfusion strategies in studies with interhospital or direct transport of patients to PTCA
centre
Study Patients Randomisation Thrombolysis PTCA
PRAGUE-2 ST q AMI ,12 h In community hospital without PTCA facility to: Streptokinase Stents used in 63%
Thrombolysis or direct PTCA
provided start interhospital transport
possible within 30 mins and distance ,120 km
DANAMI-2 ST q AMI ,12 h In community hospital or PTCA centre to: Accelerated (acc) t-PA Stents used in 81%
Thrombolysis or direct PTCA Glycoprotein IIb/IIIA
blocker in 39%
if admitted in community hospital:
provided transport to PTCA centre completed within
3 hours
CAPTIM ST q AMI ,6 h On site to: Pre-hospital acc t-PA Stents used in 81%
thrombolysis or direct PTCA + transport to PTCA
centre, provided transport duration ,1 hour
With rescue PTCA
strategy
Glycoprotein IIb/IIIA
blocker in 39%
Use of rescue PTCA: in DANAMI-2 study 1.9%, CAPTIM study 26%, PRAGUE-2 study 6.4%. Any PTCA at 30 days: in DANAMI-2 study 16.5%, CAPTIM study
70.4%.
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Because of practical limitations, it is expected that the short
door-to-balloon times reported in the randomised trials will
not be repeated in the real world.w9
A PRAGMATIC APPROACH
There is no evidence that every patient with an evolving AMI
should be referred for direct PTCA. The choice of treatment
should be based upon an assessment of the baseline risk of
the individual patient, and a risk/benefit evaluation of the
possible treatment modalities and logistics. Some patients
(the elderly, patients with antecedents of heart failure,
diabetes, stroke or bypass surgery, patients with an anterior
infarction and/or signs of heart failure or shock at admission)
are at increased risk.6 They benefit more from direct PTCA
than from thrombolytic treatment, although it should be
appreciated that this information stems from post-hoc
subgroup analyses.w20–22
The time interval from onset of symptoms to presentation
should have a central role in the selection of treatment. None
of the randomised comparisons fully took advantage of the
possibility of early diagnosis and initiation of treatment on
site, before transportation or admission, except for the
CAPTIM study.11 Patients were randomised at the site of
initial management, most often at home or the workplace, to
either pre-hospital thrombolysis or transport for direct PTCA.
Patients randomised to pre-hospital thrombolysis were also
transported to a PTCA centre for rescue PTCA. The latter was
decided upon at the discretion of the attending physician.
The median time delay between onset of symptoms and
initiation of treatment was 130 minutes for pre-hospital
thrombolysis and 190 minutes for direct PTCA. Rescue PTCA
was performed in 26% of the thrombolytic patients. At
variance with all other studies, direct PTCA was not better
than the pre-hospital thrombolysis strategy (tables 1 and 4).
More interestingly, a subgroup analysis disclosed a strong
trend toward a lower mortality and less cardiogenic shock in
patients treated with pre-hospital thrombolysis within two
hours after onset of symptoms (table 5).19 In patients
presenting later than two hours after onset of symptoms,
there was a trend of superiority of direct PTCA.
This was also found in a subgroup analysis of the
PRAGUE-2 study that revealed a similar 30 day mortality
with in-hospital thrombolysis with streptokinase and direct
PTCA in patients presenting within three hours (7.3% v
7.4%); however, if treated after three hours, 30 day mortality
with thrombolysis rose considerably compared to PTCA
(15.3% v 6.0%, respectively).9
Such an effect was not observed in the DANAMI-2 study.10
In this study 1572 patients were randomised to direct PTCA
or acc t-PA. In total, 1129 patients (72%) were randomised in
a community hospital, and 567 were subsequently trans-
ported to a PTCA centre for direct PTCA. The median
interhospital transport time was 32 minutes. No pharmaco-
logical treatment aimed at the restoration of flow was started
before transport. The median door-to-balloon time of patients
directly admitted to the PTCA centre was 26 minutes, while
for those patients initially admitted to a community hospital
it was 93 minutes. The main study finding was a 40% relative
reduction in the composite outcome (30 day death, reinfarc-
tion, stroke) in patients enrolled in the community hospitals
and 45% in patients enrolled in the PTCA centres in favour of
direct PTCA. The benefit of direct PTCA was driven by a 75%
relative reduction in reinfarction (1.6% v 6.3%), whereas
there was no difference in death and stroke. At variance with
the CAPTIM and PRAGUE study, direct PTCA was also
superior to thrombolysis in patients admitted within two
hours. This discrepancy is unclear. A subgroup effect cannot
be excluded and may have biased the results. The advantage
Table 4 Clinical events at 30 days in studies with interhospital or direct transport of
patients to a PTCA centre
PRAGUE-2 DANAMI-2 CAPTIM
Lysis PTCA Lysis PTCA Lysis PTCA
Patients (n) 421 429 782 790 419 421
Death 10.0 6.2 7.8 6.6 3.8 4.3
Reinfarction 3.1 1.4 6.3 1.6* 3.7 1.7
Stroke 2.1 0.2* 2.0 1.1 1.0 0.0
Composite 15.2 8.4* 13.7 8.0* 8.2 6.2
Rescue PTCA 6.4 1.9 26.0
Any PTCA at 30 days NR 16.5 70.4
All values are expressed as relative numbers (%).
*Outcomes which reached the level of significance.
NR, not recorded.
Table 5 Incidence of events after direct PTCA and thrombolytic treatment according to time between onset of symptoms and
randomisation
,2 hours >2 hours
Pre-hospital lysis Direct PTCA Pre-hospital lysis Direct PTCA
Time to therapy (mins) 95 (40–175) 150 (82–260) ,0.0001 195 (120–570) 258 (150–1275) ,0.0001
Death 2.2 5.7 0.06 5.9 3.7 NS
Reinfarction 4.0 1.4 NS 3.4 2.2 NS
Stroke 1.3 0.0 NS 0.6 0.0 NS
Cardiogenic shock 1.3 5.3 0.03 3.9 4.4 NS
Events are expressed in relative numbers (%), median time with interquartile range.
NS, not significant.
Modified from Steg et al,19 with permission.
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of thrombolysis over direct PTCA in patients presenting and
being treated early is, nonetheless, plausible. These patients
have a fresh thrombus, which is easily dissolved by
a thrombolytic drug, especially when administered very
early.
Rather than referring every single patient with an AMI for
direct PTCA, an integrated approach as proposed previously
and by others appears to be more appropriate.20 w23 w24 It is
based upon the assessment of: (1) time interval from onset of
symptoms to presentation; (2) baseline risk derived from
Area at risk
Small (ST shift < 15 mm ) Large (ST shift  15 mm) 
           Age < 70 years?        PTCA possible < 90 minutes?
    Yes     No      No     Yes
   Contraindication
            to lysis? On site ASA/LMWH/IIb/IIIa
Yes No
Conservative        Conservative       PTCA centre
     On site lysis
* *
Figure 2 Management of patients with ST segment elevation acute myocardial infarction and presentation ( 6 hours. ASA, aspirin; LMWH, low
molecular weight heparin; PTCA, percutaneous transluminal coronary angioplasty.
Time of diagnosis
< 2 hours after symptom onset  2 hours after symptom onset
  Contraindications to lysis?   PTCA possible < 90 minutes?
No  Yes No Yes
On site lysis     If lysis not possible * On site ASA/LMWH/IIb/IIIa
Admission       PTCA centre PTCA centre
+ possible rescue PTCA
Figure 3 Management of patients with ST segment elevation acute myocardial infarction. *Consider PTCA if on site lysis not possible.
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clinical examination and ECG; (3) risk/benefit assessment of
treatment (bleeding and intracranial bleeding, in particular;
and (4) availability and estimated time from presentation to
PTCA which includes transportation and door-to-balloon
time.
Two algorithms have been proposed (figs 2 and 3) The first
uses the estimated myocardial area at risk (total ST shift and
number of leads with shift) as the primary selection
criterion.w23 The other takes the time interval between
symptom onset and presentation as the starting point.20 w24
In both algorithms, pre-hospital thrombolysis is advocated
for patients seen very early in the course of an infarct. The
choice of the algorithm may depend on regional and
institutional issues such as population density and geogra-
phy, infrastructure, agreements with ambulance services,
health insurance companies, and policymakers.
While there is consensus that thrombolysis should
comprise the pre-hospital administration of the lytic drug,
preferably as a single bolus, in combination with aspirin and
weight adjusted low molecular weight heparin, the initial
pharmacology strategy in patients referred for direct PTCA is
the subject of investigation.w25 The objective is to induce the
TIMI 3 flow before the patient arrives in the catheterisation
laboratory without the risk of major bleeding. Abciximab
before but not at the time of PTCA has been shown to
improve outcome.w13
SUMMARY
All randomised comparisons have shown that direct PTCA is
superior to thrombolysis in patients with AMI. Yet the choice
of treatment strategy should depend on the careful evalua-
tion of the risk/benefit of treatment. Issues unrelated to this
assessment will most likely influence the selection of
treatment in daily practice. Two algorithms have been
proposed which differ in the primary selection or triage
criterion (area at risk versus time interval). Based upon local
and regional factors, one or the other may be chosen.
The role of rescue and systematic PTCA after thrombolysis
needs further elucidation. At present, it cannot be proposed
as a standard treatment.
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